Russell Frank Company’s Revance Therapeutics, Inc. RVNC Stock Holding History

Russell Frank Company’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-38,974	Closed	-$1.38M	–	3051
2015 Q4	$1.38M	Buy	+38,974	New	+$1.35M	﹤0.01%	2055
2014 Q3	–	Sell	-35,173	Closed	-$1.09M	–	2901
2014 Q2	$1.09M	Buy	+35,173	New	+$1.1M	﹤0.01%	2029

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NHG

NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Frank Company's RVNC Position: Q1 2016 in Review

Russell Frank Company sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2016, closing a stake of 38,974 shares — an estimated $1.38M sold.

Russell Frank Company first reported a position in RVNC in Q2 2014 and held it in 2 quarters. The position peaked at $1.38M in Q4 2015. 86 funds tracked by Wall St. Rank hold RVNC as of Q1 2016.

Russell Frank Company reported no remaining Revance Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 38,974 Revance Therapeutics, Inc. shares in Q1 2016, an estimated $1.38M.
Russell Frank Company first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
Russell Frank Company's Revance Therapeutics, Inc. position peaked at $1.38M in Q4 2015.
86 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.